Literature DB >> 9355976

p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis.

M Jiang1, Z M Shao, J Wu, J S Lu, L M Yu, J D Yuan, Q X Han, Z Z Shen, J A Fontana.   

Abstract

p21/waf1/cip1 and mdm-2 are downstream effectors of p53. p21 plays a major role in negatively regulating cell-cycle progression, while mdm-2 inhibits p53 effects, and its role has been implicated in oncogenesis. In this study, we investigated the expression profiles of p21, mdm-2 and p53 in human breast-carcinoma tissues. The aim was to determine whether a correlation exists between the expression profiles of these markers and tumor differentiation, ER status and prognosis. We studied tumor specimens obtained from 106 patients and found a highly significant association among low histology grade, p53 over-expression, high mdm-2 expression and lack of p21 expression. Our studies also demonstrate that, in human breast cancer, low levels of p21 and higher mdm-2 levels directly correlate with the onset of lymph-node metastases and shortened patient survival. Furthermore, the expression profiles of p21, mdm-2 and p53 were independently correlated with patient survival.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9355976     DOI: 10.1002/(sici)1097-0215(19971021)74:5<529::aid-ijc9>3.0.co;2-5

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

1.  Loss of nuclear p21(Cip1/WAF1) during neoplastic progression to metastasis in gamma-irradiated p21 hemizygous mice.

Authors:  Robert W Engelman; Rosalind J Jackson; Domenico Coppola; Walker Wharton; Alan B Cantor; W Jack Pledger
Journal:  Exp Mol Pathol       Date:  2007-01-04       Impact factor: 3.362

2.  Relationship and prognostic significance of phospho-(serine 166)-murine double minute 2 and Akt activation in node-negative breast cancer with regard to p53 expression.

Authors:  K J Schmitz; F Grabellus; R Callies; J Wohlschlaeger; F Otterbach; R Kimmig; B Levkau; K W Schmid; H A Baba
Journal:  Virchows Arch       Date:  2005-10-06       Impact factor: 4.064

Review 3.  Cip/Kip cell-cycle inhibitors: a neuro-oncological perspective.

Authors:  T G Mainprize; M D Taylor; J T Rutka; P B Dirks
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

4.  p21(waf) correlates with DNA replication but not with prognosis in invasive breast cancer.

Authors:  U J Göhring; A Bersch; M Becker; W Neuhaus; T Schöndorf
Journal:  J Clin Pathol       Date:  2001-11       Impact factor: 3.411

5.  Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells.

Authors:  S Cariou; J C Donovan; W M Flanagan; A Milic; N Bhattacharya; J M Slingerland
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

Review 6.  Molecular chemotherapy for breast cancer.

Authors:  A Patterson; A L Harris
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

7.  The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models.

Authors:  Wei Wang; Jiang-Jiang Qin; Sukesh Voruganti; Kalkunte S Srivenugopal; Subhasree Nag; Shivaputra Patil; Horrick Sharma; Ming-Hai Wang; Hui Wang; John K Buolamwini; Ruiwen Zhang
Journal:  Nat Commun       Date:  2014-10-01       Impact factor: 14.919

Review 8.  Cell cycle regulators and their abnormalities in breast cancer.

Authors:  P L Fernández; P Jares; M J Rey; E Campo; A Cardesa
Journal:  Mol Pathol       Date:  1998-12

9.  High-sensitivity array analysis of gene expression for the early detection of disseminated breast tumor cells in peripheral blood.

Authors:  K J Martin; E Graner; Y Li; L M Price; B M Kritzman; M V Fournier; E Rhei; A B Pardee
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

10.  Expression of Smad4, TGF-βRII, and p21waf1 in esophageal squamous cell carcinoma tissue.

Authors:  Hui Cheng; Cheng Chen; L U Liu; N A Zhan; Benhui Li
Journal:  Oncol Lett       Date:  2015-04-23       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.